Insulin auto-immunity: Implications for the prevention of Type 1 diabetes mellitus

Expert Review of Clinical Immunology

Volumn 5, Issue 1, 2009, Pages 55-62

  Wicklow, Brandy A ^a   Polychronakos, Constantin ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Immune tolerance; Immunotherapy; Insulin auto antibodies; Prevention therapy; Type 1 diabetes

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; PROINSULIN;

AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION; GENE LOCUS; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 77649172757     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.5.1.55     Document Type: Review

References (48)

1. Ziegler A-G, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with Type 1 diabetes. Diabetes 48, 460-468 (1999).
2. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler A. Brief communication: early appearance of islet autoantibodies predicts childhood Type 1 diabetes in offspring of diabetic parents. Ann. Int. Med. 140(11), 882-886 (2004).
3. Barker JM, Barriga KJ, Yu L et al. Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY). J. Clin. Endocrinol. Metab. 89(8), 3896-3902 (2004).
4. Kimpimaki T, Kulmala P, Savola K et al. Natural history of B-cell autoimmunity in young children with increased genetic susceptibility to Type 1 diabetes recruited from the general population. J. Clin. Endocrinol. Metab. 87(10), 4572-4579 (2002).
5. Stene LC, Witso E, Torjesen PA et al. Islet autoantibody development during follow-up of high-risk children from the general Norwegian population from three months of age: design and early results from the MIDIA Study. J. Autoimmun. 29, 44-51 (2007).
6. Liping Y, Robles DT, Abiru N et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl Acad. Sci. 97(4), 1701-1706 (2000).
7. Burton AR, Vincent E, Arnold PY et al. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes 57, 1321-1330 (2008).
8. Vafiadis P, Bennett S, Todd J et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 15(3), 289-292 (1997).
9. Vafiadis P, Bennett S, Colle E, Grabs R, Goodyer C, Polychronakos C. Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leukocytes. J. Autoimmun. 9(3), 397-403 (1996).
10. Vafiadis P, Ounissi-Benkalha H, Palumbo M et al. Class III alleles of the variable number tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to Type 1 diabetes. J. Clin. Endocrinol. Metab. 86(8), 3705-3710 (2001).
11. Smith KM, Olson DC, Hirose R, Hanahan D. Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. Int. Immunol. 9(9), 1355-1365 (1997).
12. Jolicoeur C, Hanahan D, Smith KM. T-cell tolerance toward a transgenic B-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc. Natl Acad. Sci. USA 91, 6707-6711 (1994).
13. Heath WR, Allison J, Hoffmann MW et al. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature 359, 547-549 (1992).
14. Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435, 220-223 (2005).
15. Moriyama H, Nagata M, Arai T et al. Insulin as a T cell antigen in Type 1 diabetes supported by the evidence from the insulin knockout NOD mice. Diabetes Res. Clin. Pract. 77(Suppl. 1), S155-S160 (2007).
16. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance. Diabetes 51, 1383-1390 (2002).
17. Faideau B, Briand S, Lotton C et al. Expression of preproinsulin-2 gene shapes the immune response to preproinsulin in normal mice. J. Immunol. 172(1), 25-33 (2004).
18. Faideau B, Lotton C, Lucas B et al. Tolerance to proinsulin-2 is due to radioresistant thymic cells. J. Immunol. 177(1), 53-60 (2006).
19. Thebault-Baumont K, Dubois-Laforgue D, Krief P et al. Acceleration of Type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J. Clin. Invest. 111(6), 851-857 (2003).
20. Babaya N, Nakayama M, Moriyama H et al. A new model of insulin-deficient diabetes: male NOD mice with a single copy of Ins1 and no Ins2. Diabetologia 49(6), 1222-1228 (2006).
21. Nakayama M, Babaya N, Miao D et al. Long-term prevention of diabetes and marked suppression of insulin autoantibodies and insulinitis in mice lacking native insulin B9-23 sequence. Ann. NY Acad. Sci. 1079, 122-129 (2006).
22. Wegmann D, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur. J. Immunol. 24(8), 1853-1857 (1994).
23. Daniel D, Gill R, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25(4), 1056-1062 (1995).
24. Kobayashi M, Jasinski J, Liu E et al. Conserved T cell receptor-chain induces insulin autoantibodies. Proc. Natl Acad. Sci. USA 105(29), 10090-10094 (2008).
25. Abiru N, Maniatis A, Yu L et al. Peptide and major histocompatibility complex specific breaking of humoral tolerance to native insulin with the B:9-23 peptide in diabetes-prone and normal mice. Diabetes 50(6), 1274-1281 (2001).
26. Krishnamurthy B, Dudek NL, McKenzie MD et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J. Clin. Invest. 116(12), 3258-3265 (2006).
27. Krishnamurthy B, Mariana L, Gellert SA et al. Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J. Immunol. 180, 4458-4464 (2008).
28. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler A-G, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to Type 1 diabetes. J. Clin. Invest. 114(4), 589-597 (2004).
29. Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of Type 1 diabetic subjects recognize an insulin epitope. Nature 435, 224-228 (2005).
30. Arif S, Tree T, Astill T et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113(3), 346-349 (2004).
31. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl Acad. Sci. USA 93, 956-960 (1996).
32. Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC. Intranasal vaccination with proinsulin DNA induces regulatory CD4 T cells that prevent experimental autoimmune diabetes. J. Immunol. 176, 4608-4615 (2006).
33. Ploix C, Bergerot I, Durand A, Czerkinsky C, Holmgren J, Thivolet C. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4 regulatory T-cells. Diabetes 48, 2150-2156 (1999).
34. Kobayashi M, Abiru N, Arakawa T et al. Altered B:9-23 insulin, when administered intranasally with cholera toxin adjuVan t, supresses the expression of insulin autoantibodies and prevents diabetes. J. Immunol. 179, 2082-2088 (2007).
35. Du W, Wong FS, Li MO et al. TGF-b signaling is required for the function of insulin-reactive T regulatory cells. J. Clin. Invest. 116(5), 1360-1370 (2006).
36. Peng J, Dicker B, Du W et al. Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF-producing non-pathogenic regulatory cells folllowing FoxP3 transduction. J. Autoimmun. 28, 188-200 (2007).
37. Bresson D, Togher L, Rodrigo E et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116(5), 1371-1381 (2006).
38. Bergerot I, Arreaza GA, Cameron MJ et al. Insulin B-chain reactive CD4 regulatory T-cells induced by oral insulin treatment protect from Type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 48, 1720-1729 (1999).
39. Homann D, Dyrberg T, Petersen J, Oldstone MB, Von Herrath MG. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J. Immunol. 163, 1833-1838 (1999).
40. Von Herrath M, Dyrberg T, Oldstone M. Oral insulin treatment suppresses virus-induced antigen-specific destruction of ? cells and prevents autoimmune diabetes in transgenic mice. J. Clin. Invest. 98, 1324-1331 (1996).
41. Skyler JS, Krischer JP, Wolfsdorf J et al.; for The Diabetes Prevention Trial - Type 1 Study Group. Effects of oral insulin in relatives of patients with Type 1 diabetes. Diabetes Care 28(5), 1068-1076 (2005).
42. Group DPT-TDS. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1685-1691 (2002).
43. Harrison LC, Honeyman MC, Steele CE et al. Pancreatic B-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for Type 1 diabetes. Diabetes Care 27(10), 2348-2355 (2004).
44. Harrison LC. Vaccination against self to prevent autoimmune disease: the Type 1 diabetes model. Immunol. Cell Biol. 86, 139-145 (2008).
45. Näntö-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent Type 1 diabetes in children with LA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372(9651), 1746-1755 (2008).
46. Shoda LK, Young DL, Ramanujan S et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126 (2005).
47. Achenbach P, Barker J, Bonifacio E; Pre-POINT Study Group. Modulating the natural history of Type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr. Diabetes Rep. 8(2), 87-93 (2008).
48. Kupila A, Sipila J, Keskinen P et al. Intranasally administered insulin intended for prevention of Type 1 diabetes - a safety study in healthy adults. Diabetes Metab. Res. Rev. 19, 415-420 (2003).